Search results
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 2 days agoTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 3 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
Amgen (AMGN) Scheduled to Post Earnings on Thursday
ETF DAILY NEWS· 6 days agoAmgen (NASDAQ:AMGN – Get Free Report) is set to announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $3.82 per share ...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort...
Benzinga· 2 days agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
722 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by McAdam LLC
ETF DAILY NEWS· 4 days agoMcAdam LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission ...
Is Algae Oil the New Fish Oil?
Men's Health via Yahoo News· 5 days agoAlgae oil is all the rage right now as a vegetarian replace to fish oil. Dietitians explain its health benefits, uses, and risks associated with using...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $26.56
ETF DAILY NEWS· 3 days agoArcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 5 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...